Endo begins manufacture of Novavax’s potential COVID-19 vaccine
NEW YORK (US) – Generic drugmaker Endo said on Friday it was producing Novavax Inc’s experimental COVID-19 vaccine. Its shares have gone up 10% before the trading bell.
This has come after Novavax launched a late-stage trial of the vaccine candidate, NVX‑CoV2373, in the UK, a day ago.
Endo said it has struck a deal with Novavax and its unit Par Sterile has started producing the final drug product. The initial batches will be used during the Novavax’s phase-3 clinical trial in the US.
Two ongoing mid-stage trials that began in August are also testing NVX‑CoV2373 currently.